Biotricity Inc. (Biotricity) today announced ongoing improvements in operational efficiency, scalability and margin performance driven by the latest enhancements to the company’s proprietary AI Cloud platform.  The latest version of Biotricity’s AI Cloud has improved the company’s tech stack efficiency by 20%, which is expected to result in a topline margin improvement of 200 to 300 basis points (2 to 3%) in the coming quarters. The next version of the AI Cloud, currently under development, is anticipated to enhance the tech stack by another 20%, contributing to an additional margin improvement of 100 to 200 basis points (1 to 2%). These across-the-board improvements are accelerating Biotricity’s path to breakeven and achieving positive cash flow.

Biotricity Inc. (Biotricity) today announced the expanding development of its future Cardiac AI Cloud platform. The new platform is focused on predictive monitoring to help assist physicians and users to identify issues before they occur, supporting earlier interventions, reducing readmissions, and lowering healthcare costs. Biotricity’s product portfolio is already one of the most comprehensive remote cardiac monitoring portfolios globally. This expansion will further enhance its existing products while providing additional advantages.

Biotricity Inc. (Biotricity) today reported that it achieved a record $14 million annualized revenue run rate in August, extending its growth by over eight percent from the previously announced $13 million run rate.  In its Corporate Impact Report published last spring, Biotricity described both “better patient outcomes and substantial cost savings” for patients using its devices.

Biotricity Inc. (Biotricity) today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on July 18, 2023 informing that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Consequently, Biotricity is now in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market.

Biotricity Inc. (Biotricity) today announced that it will effect a reverse stock split of its common stock.  Biotricity expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on July 3, 2023.  The reverse stock split was approved by the Board of Directors of the Company and is intended to increase the per share trading price of the Company’s common stock to satisfy the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Biotricity Inc. (Biotricity) today reported that it reached a record $13 million annualized revenue run rate in April,  further extending its growth by over eight percent from the $12 million run rate it announced for March 2023.  In its Corporate Impact Report published earlier this month, Biotricity described both “better patient outcomes and substantial cost savings” for patients using its devices.